Literature DB >> 16539279

Circulating levels of beta2-glycoprotein I in thrombotic disorders and in inflammation.

F Lin1, R Murphy, B White, J Kelly, C Feighery, R Doyle, S Pittock, J Moroney, O Smith, W Livingstone, C Keenan, J Jackson.   

Abstract

Beta2-glycoprotein I (beta2GPI) is a plasma protein suspected to have a role in inhibition of thrombosis. This suspicion is reinforced by the observation that beta2GPI is the major target for autoantibodies in the antiphospholipid syndrome. However, little is known about its circulating levels in common thrombotic diseases or inflammation. We measured beta2GPI levels in 344 healthy controls, 58 normal pregnancies, 102 patients with non-haemorrhagic stroke, 121 patients with acute coronary syndrome and 200 patients with elevated C-reactive protein (CRP). In healthy individuals, we found a strong positive correlation between age and beta2GPI concentration (r = 0.274, P < 0.001) and that beta2GPI levels fall significantly after the eighth week of pregnancy (P = 0.002). We also found significantly reduced levels of beta2GPI in patients with stroke and in elderly patients with myocardial syndrome (P = 0.013 and 0.043). However, in neither group did beta2GPI levels change in the following six months, suggesting that the reduced levels were not a transient post-event phenomenon. In patients with inflammation, beta2GPI levels showed a significant negative correlation with CRP (r = -0.284, P < 0.001) and positively correlated with albumin and transferrin (r = 0.372 and 0.453, respectively with P < 0.001 for both). Furthermore, the largest reduction in beta2GPI levels occurred in patients with the highest CRP values (P < 0.001).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16539279     DOI: 10.1191/0961203306lu2270oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  14 in total

1.  Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I.

Authors:  A Artenjak; I Locatelli; H Brelih; D M Simonič; Z Ulcova-Gallova; J Swadzba; J Musial; T Iwaniec; L Stojanovich; F Conti; G Valesini; T Avčin; J W Cohen Tervaert; Y Shoenfeld; M Blank; A Ambrožič; S Sodin-Semrl; B Božič; S Čučnik
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  β2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus.

Authors:  Joanne H Reed; Robert M Clancy; Anthony W Purcell; Mimi Y Kim; Tom P Gordon; Jill P Buyon
Journal:  J Immunol       Date:  2011-05-20       Impact factor: 5.422

Review 3.  Clinical relevance of β₂-glycoprotein-I plasma levels in antiphospholipid syndrome (APS).

Authors:  Alessandra Banzato; Vittorio Pengo
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.592

4.  Antı-β2 Glycoprotein I Antibodies in Children with Rheumatologic Disorders.

Authors:  Elif Azarsiz; Gamze Eman; Sanem Eren Akarcan; Ezgi Ulusoy Severcan; Neslihan Karaca; Guzide Aksu; Necil Kutukculer
Journal:  Indian J Clin Biochem       Date:  2017-11-10

5.  Anti Saccharomyces cerevisiae Antibodies in Patients With Anti-β2 Glycoprotein I Antibodies.

Authors:  Amani Mankaï; Skander Layouni; Ibtissem Ghedira
Journal:  J Clin Lab Anal       Date:  2016-04-07       Impact factor: 2.352

6.  Structural insights into recognition of beta2-glycoprotein I by the lipoprotein receptors.

Authors:  Dmitri Beglov; Chang-Jin Lee; Alfredo De Biasio; Dima Kozakov; Ryan Brenke; Sandor Vajda; Natalia Beglova
Journal:  Proteins       Date:  2009-12

7.  β₂-glycoprotein I inhibits VEGF-induced endothelial cell growth and migration via suppressing phosphorylation of VEGFR2, ERK1/2, and Akt.

Authors:  Wen-Chin Chiu; Jan-Yu Lin; Tzong-Shyuan Lee; Li-Ru You; An-Na Chiang
Journal:  Mol Cell Biochem       Date:  2012-09-06       Impact factor: 3.396

8.  Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome.

Authors:  Alexey Kolyada; Andrew Porter; Natalia Beglova
Journal:  Blood       Date:  2013-11-25       Impact factor: 22.113

9.  A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome.

Authors:  Alexey Kolyada; Chang-Jin Lee; Alfredo De Biasio; Natalia Beglova
Journal:  PLoS One       Date:  2010-12-15       Impact factor: 3.240

10.  Optimization of unnicked β2-glycoprotein I and high avidity anti-β2-glycoprotein I antibodies isolation.

Authors:  Andrej Artenjak; Adrijana Leonardi; Igor Križaj; Aleš Ambrožič; Snezna Sodin-Semrl; Borut Božič; Saša Cučnik
Journal:  J Immunol Res       Date:  2014-01-23       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.